Madrigal Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Madrigal Pharmaceuticals
MDGL Stock  USD 481.00  2.17  0.45%   
Madrigal Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Madrigal Pharmaceuticals' valuation are provided below:
Gross Profit
705.5 M
Profit Margin
(0.39)
Market Capitalization
11.1 B
Enterprise Value Revenue
13.9416
Revenue
740.6 M
There are over one hundred nineteen available fundamental ratios for Madrigal Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to check Madrigal Pharmaceuticals' last-minute fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 6.2 B this year. Enterprise Value is expected to rise to about 6.2 B this year

Madrigal Pharmaceuticals Total Revenue

217.51 Million

Check Madrigal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Madrigal Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 17.7 M, Other Operating Expenses of 818.7 M or Research Development of 285.8 M, as well as many indicators such as Price To Sales Ratio of 39.81, Dividend Yield of 0.0073 or PTB Ratio of 8.22. Madrigal financial statements analysis is a perfect complement when working with Madrigal Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Madrigal Stock
Check out the analysis of Madrigal Pharmaceuticals Correlation against competitors.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

Madrigal Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.3 B1.2 B390.4 M
Slightly volatile
Total Stockholder Equity910.9 M867.5 M290.7 M
Slightly volatile
Common Stock Total Equity4.3 K2.3 K4.1 K
Slightly volatile
Common Stock Shares Outstanding25.7 M24.5 M11.5 M
Slightly volatile
Liabilities And Stockholders Equity1.3 B1.2 B390.4 M
Slightly volatile
Other Stockholder Equity3.1 B2.9 B995.5 M
Slightly volatile
Total Liabilities347.6 M331 M99.7 M
Slightly volatile
Common Stock3 K1.8 K4 K
Slightly volatile
Other Current Liabilities150.6 M143.4 M46.9 M
Slightly volatile
Total Current Liabilities204.4 M194.7 M66.4 M
Slightly volatile
Property Plant And Equipment Net2.2 M4.1 M1.8 M
Slightly volatile
Accounts Payable52.6 M50.1 M14.5 M
Slightly volatile
Cash76.8 M115 M81.4 M
Slightly volatile
Non Current Assets Total8.8 M8.4 M2.9 M
Slightly volatile
Non Currrent Assets Other719.9 K1.4 M800.8 K
Slightly volatile
Cash And Short Term Investments1.1 B1.1 B369.7 M
Slightly volatile
Short Term Investments997.7 M950.2 M286.9 M
Slightly volatile
Other Current Assets22.7 M21.6 M4.9 M
Slightly volatile
Property Plant And Equipment Gross2.2 M4.1 M1.8 M
Slightly volatile
Total Current Assets1.2 B1.2 B387.8 M
Slightly volatile
Short and Long Term Debt Total144.4 M137.5 M38 M
Slightly volatile
Short Term Debt1.1 M1.1 M5.1 M
Slightly volatile
Long Term Debt Total59.5 M56.7 M43.3 M
Slightly volatile
Capital Surpluse1.4 B1.3 B766.7 M
Slightly volatile
Capital Lease Obligations2.4 M2.3 M904.6 K
Slightly volatile
Short and Long Term Debt49.9 M55.9 M47.2 M
Slightly volatile
Net Invested Capital1.1 B1 B381.3 M
Slightly volatile
Net Working Capital1 B993.2 M379.1 M
Slightly volatile
Capital Stock1.6 K1.8 K2 K
Slightly volatile
Non Current Liabilities Other445.9 K445.1 K383.3 K
Slightly volatile

Madrigal Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses818.7 M779.7 M232.1 M
Slightly volatile
Research Development285.8 M272.2 M125.1 M
Slightly volatile
Total Operating Expenses811.2 M772.5 M226.9 M
Slightly volatile
Depreciation And Amortization937.1 K986.4 K3.3 M
Slightly volatile
Selling General Administrative525.3 M500.3 M106.3 M
Slightly volatile
Interest Income56.3 M53.7 M13.2 M
Slightly volatile
Non Operating Income Net Other4.1 M2.5 M2.2 M
Slightly volatile
Reconciled Depreciation1.3 M1.3 M374.9 K
Slightly volatile
Selling And Marketing Expenses86.4 M97.2 M106.1 M
Slightly volatile

Madrigal Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow70.4 M114.9 M73.3 M
Slightly volatile
Depreciation946.6 K626.4 K557.8 K
Pretty Stable
Other Non Cash Items2.3 M2.4 M6.1 M
Very volatile
Capital Expenditures732.3 K1.3 M529.8 K
Slightly volatile
Total Cash From Financing Activities887.6 M845.3 M263.2 M
Slightly volatile
End Period Cash Flow76 M120.8 M80.7 M
Slightly volatile
Stock Based Compensation96.5 M91.9 M27.9 M
Slightly volatile
Change Receivables6.3 K6.6 K20 K
Slightly volatile
Change To Netincome38.2 M36.4 M17.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio39.8141.9143.3433
Slightly volatile
Dividend Yield0.00730.00830.009
Slightly volatile
PTB Ratio8.227.837.8509
Pretty Stable
Days Sales Outstanding119125236
Slightly volatile
Book Value Per Share49.8740.7841.0567
Pretty Stable
Average Payables472.1 K497 K857.8 K
Slightly volatile
Stock Based Compensation To Revenue0.480.510.8522
Slightly volatile
Capex To Depreciation1.411.892.1612
Very volatile
PB Ratio8.227.837.8509
Pretty Stable
EV To Sales39.9342.0341.7095
Slightly volatile
Inventory Turnover0.140.160.1791
Slightly volatile
Days Of Inventory On Hand1.6 K1.8 K2 K
Slightly volatile
Payables Turnover0.160.1430.2035
Slightly volatile
Sales General And Administrative To Revenue1.661.752.6373
Slightly volatile
Research And Ddevelopement To Revenue1.441.512.5979
Slightly volatile
Capex To Revenue0.00890.00930.0473
Slightly volatile
Cash Per Share79.6750.0760.4398
Pretty Stable
Days Payables Outstanding2.2 K2.3 K212.6 K
Pretty Stable
Income Quality0.570.880.8103
Slightly volatile
Intangibles To Total Assets0.00360.00410.0045
Slightly volatile
Current Ratio7.075.4910.2696
Very volatile
Tangible Book Value Per Share49.8640.5341.0283
Pretty Stable
Receivables Turnover2.863.013.1111
Slightly volatile
Shareholders Equity Per Share49.8740.7841.0567
Pretty Stable
Debt To Equity0.150.140.182
Slightly volatile
Capex Per Share0.07510.0790.1872
Slightly volatile
Revenue Per Share7.247.627.8032
Slightly volatile
Interest Debt Per Share8.267.266.4563
Pretty Stable
Debt To Assets0.0880.10.0949
Pretty Stable
Graham Number174196214
Slightly volatile
Operating Cycle1.6 K2.4 K2.1 K
Pretty Stable
Price Book Value Ratio8.227.837.8509
Pretty Stable
Days Of Payables Outstanding2.2 K2.3 K212.6 K
Pretty Stable
Ebt Per Ebit1.530.842.2519
Pretty Stable
Effective Tax Rate0.260.30.3284
Slightly volatile
Company Equity Multiplier1.311.241.4288
Pretty Stable
Total Debt To Capitalization0.230.160.1315
Pretty Stable
Debt Equity Ratio0.150.140.182
Slightly volatile
Quick Ratio7.065.3110.2466
Very volatile
Net Income Per E B T0.540.90.6826
Slightly volatile
Cash Ratio0.650.683.4474
Slightly volatile
Days Of Inventory Outstanding1.6 K1.8 K2 K
Slightly volatile
Days Of Sales Outstanding119125236
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0207
Slightly volatile
Price To Book Ratio8.227.837.8509
Pretty Stable
Fixed Asset Turnover37.0835.3134.603
Slightly volatile
Debt Ratio0.0880.10.0949
Pretty Stable
Price Sales Ratio39.8141.9143.3433
Slightly volatile
Asset Turnover0.150.160.1619
Slightly volatile
Price Fair Value8.227.837.8509
Pretty Stable

Madrigal Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.2 B5.9 B2.6 B
Slightly volatile
Enterprise Value6.2 B5.9 B2.6 B
Slightly volatile

Madrigal Fundamental Market Drivers

Forward Price Earnings666.6667
Cash And Short Term Investments926.3 M

Madrigal Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Madrigal Pharmaceuticals Financial Statements

Madrigal Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Madrigal Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-38.7 K-36.8 K
Total Revenue207.2 M217.5 M
Cost Of Revenue5.6 M5.9 M
Stock Based Compensation To Revenue 0.51  0.48 
Sales General And Administrative To Revenue 1.75  1.66 
Research And Ddevelopement To Revenue 1.51  1.44 
Capex To Revenue 0.01  0.01 
Revenue Per Share 7.62  7.24 
Ebit Per Revenue(2.49)(2.61)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
How To Invest In Madrigal
Details
Is Madrigal Stock a good investment?
Details
What is Madrigal Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Madrigal Pharmaceuticals Correlation against competitors.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(12.89)
Revenue Per Share
33.392
Quarterly Revenue Growth
3.62
Return On Assets
(0.16)
Return On Equity
(0.41)
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY